Kathy Hodgkinson and Daryl Pullman propose that high risk/high recurrence genetic diseases should come under the purview of public health.
Françoise Baylis responds to the recently announced birth of the world’s first genome edited babies and raises concerns about the scientific practice and ethical accountability.
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.


